Relay Therapeutics (RLAY) has shared an announcement.
Relay Therapeutics, Inc. has announced a landmark clinical trial collaboration with Pfizer to develop treatments for a specific type of metastatic breast cancer. Additionally, Relay unveiled three new pre-clinical programs targeting vascular malformations, Fabry disease, and an innovative NRAS-selective inhibitor. These announcements underscore the potential of Relay’s Dynamo™ platform in driving drug discovery and the company’s commitment to addressing significant unmet medical needs. Relay’s forward-looking statements highlight their strategic plans, regulatory engagements, and the anticipated therapeutic benefits of their diverse pipeline.
For an in-depth examination of RLAY stock, go to TipRanks’ Stock Analysis page.
